These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 33122346)

  • 1. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At the bench: Engineering the next generation of cancer vaccines.
    Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
    J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
    Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of tumour peptide vaccines: From universalization to personalization.
    Ma M; Liu J; Jin S; Wang L
    Scand J Immunol; 2020 Jun; 91(6):e12875. PubMed ID: 32090366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
    Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
    Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?
    Liu Q; Wu P; Lei J; Bai P; Zhong P; Yang M; Wei P
    Int J Biol Macromol; 2024 Nov; 279(Pt 4):135541. PubMed ID: 39270889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
    Blass E; Ott PA
    Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.
    Wu DW; Jia SP; Xing SJ; Ma HL; Wang X; Tang QY; Li ZW; Wu Q; Bai M; Zhang XY; Fu XF; Jia MM; Tang Y; Chen L; Li N
    Clin Exp Med; 2024 Sep; 24(1):229. PubMed ID: 39325256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM; Jablons D; Kratz JR
    Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.